drug
capmatinib hydrochloride
Marketedupdated 5mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying capmatinib hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 6, 2027
215 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jul 22, 2035formulationUS 10596178
- Jul 22, 2035formulationUS 10596178
- Jul 22, 2035formulationUS 12208101
- Jul 22, 2035formulationUS 12208101
- Nov 19, 2032compositionUS 7767675
- Nov 19, 2032compositionUS 7767675
- Jun 5, 2031compositionUS 84206454.7y
- Jun 5, 2031compositionUS 84206454.7y
- May 20, 2029method-of-use (U-2813)US 89011232.6y
- May 20, 2029method-of-use (U-2813)US 89011232.6y
- Nov 19, 2027method-of-use (U-2813)US 120844491.1y
- Nov 19, 2027method-of-use (U-2813)US 120844491.1y
- Nov 19, 2027compositionUS 84613301.1y
- Nov 19, 2027compositionUS 84613301.1y
FDA exclusivities (2)
- May 6, 2027ODE-291Orphan Drug (7y)215d
- May 6, 2027ODE-291Orphan Drug (7y)215d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that